Effect of vitamin D3 on serum lipid profile and HbA1c levels in type 2 diabetes mellitus: a randomized controlled study

Shadi Behshad; Mohammad Malekaneh; Gholamreza Anani Sarab; Yaser Mohammadi; Azam Rezaei Farimani

Shadi Behshad Department of Clinical Biochemistry, Faculty of Medicine, Birjand University of Medical sciences, Birjand, Iran
Mohammad Malekaneh Department of Clinical Biochemistry, Faculty of Medicine, Birjand University of Medical sciences, Birjand, Iran
Gholamreza Anani Sarab Medical Toxicology and Drug Abuse Research Center (MTDRC), Birjand University of Medical Sciences, Birjand, Iran
Yaser Mohammadi Qaen School of Nursing and Midwifery, Birjand University of Medical Sciences, Birjand, Iran
Azam Rezaei Farimani Department of Clinical Biochemistry, School of Medicine, Cardiovascular Diseases Research Center, Birjand University of Medical Sciences, Birjand, Iran

Keywords: diabetes, VD3 supplementation, HbA1c, lipid profile

Abstract

The purpose of this study was to review the effect of vitamin D3 (VD3) supplementation on glycemic control and lipid profile in patients with Type 2 Diabetes Mellitus (T2DM). A total of 68 T2DM patients with hemoglobin A1C (HbA1c)>6.5 and 25(OH) VD3<30 ng/ml were included in the study. They were randomly divided into two groups: placebo (n=34), and VD3 (n=34). Patients received weekly (VD3 (50,000 IU)/placebo) for 8 weeks. HbA1c levels, FBS and lipid profiles were assessed at baseline and after 8 weeks. A number of 62 people included VD3 (n=30) and placebo (n=32) completed the study, 25(OH) VD3 serum increased significantly after 8 weeks in the VD3 group compared to the placebo group (P<0.001). HbA1c levels, slightly higher, had decreased in the VD3 group compared to the placebo group (-0.35±1.2 vs. -0.13±1.50%, P=0.50). FBS levels slightly decreased in the VD3 group, compared to the placebo group (-6.93±39.57 vs. 5.53±42.21 mg/dl, P=0.07). In contrast to the slight decrease in total cholesterol (TC) and LDL levels in the VD3 group, was observed a slight increase in TC and LDL levels in the placebo group, and this increase was almost significant for TC (-1.26±36.72 vs. 14.65±41.56 mg/dl, P=0.05). The effect of VD3 may increase in improving hyperglycemia and lipid profile levels with increasing intervention time and sample size.